Announcements Trials
Browse Landscape

Phase

Phase 2 94Phase 1 19Phase 1/2 13Phase NA 4Phase 3 4Phase EARLY_PHASE1 3Phase 4 3Phase 2/3 2

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × OTHER × daratumumab × Clear all
NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

University of Turin, Italy

Phase 4 Active not recruiting
450 enrolled
Plasma cell

Multiple Myeloma

NCT05511428 2025-11-21

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Thomas Jefferson University

Phase 4 Completed
20 enrolled 38 charts
Plasma cell

Multiple Myeloma

NCT06409702 2025-06-12

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
59 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡